The hematology market is experiencing significant growth driven by the increasing prevalence of blood-related disorders, advancements in research and product development, and the rising number of elderly individuals vulnerable to these conditions. Additionally, the growing adoption and awareness of minimally invasive procedures have further boosted the demand for hematology devices, supporting the market’s expansion during the forecast period from 2024 to 2030.

LAS VEGAS, Dec. 12, 2024 /PRNewswire/ — DelveInsight’s Hematology Market Insights report provides the current and forecast market analysis, individual leading hematology companies’ market shares, challenges, hematology market drivers, barriers, trends, and key market hematology companies in the market.

Key Takeaways from the Hematology Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global hematology market during the forecast period. 
• In the type segment of the hematology market, coagulation analyzers are estimated to hold a higher share of the hematology market during the forecast period (2024-2030).
• Notable hematology companies such as Sysmex Corporation, Danaher, Nihon Kohden Corporation, Siemens Healthcare GmbH, Abbott, Boule Diagnostics, Bio-Rad Laboratories, Inc., Biosystems S.A., Diatron, EKF Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co., Erba Mannheim, Ortho Clinical Diagnostics, Abaxis, Heska Corporation, F. Hoffmann-La Roche Ltd, Horiba Ltd., Neomedica, Thermo Fisher Scientific, Agilent, and several others, are currently operating in the hematology market.
• In December 2024, Immune-Onc Therapeutics, Inc. shared updated results from its Phase 1b expansion cohort study of IO-202. This first-in-class anti-LILRB4 antibody was evaluated in combination with azacitidine (AZA) for the treatment of chronic myelomonocytic leukemia (CMML). The latest findings were presented during an oral session at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, California.
• In December 2024, BeiGene, Ltd. showcased new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting, highlighting its leadership in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) through the ongoing clinical success of BRUKINSA (zanubrutinib) and notable progress in its pipeline developments.
• In December 2024, Nurix Therapeutics, Inc. shared new encouraging clinical data from patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated in the Phase 1a/1b clinical trial of its Bruton’s tyrosine kinase (BTK) degrader, NX-5948.
• In December 2024, Bristol Myers Squibb shared results from 18 presentations that underscore its leadership in cell therapy. The data highlighted the effectiveness, durability, and safety of existing therapies for blood cancers, while also showcasing the promise of its pipeline for future applications, including autoimmune diseases. These findings, which span a wide range of potential targets across various disease areas, were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
• In December 2024, Taiho Oncology, Inc. shared the findings of two studies on oral treatments for patients with myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasm (MPN) at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), held from December 7-10, 2024, in San Diego.

To read more about the latest highlights related to the hematology market, get a snapshot of the key highlights entailed in the Global Hematology Market Report

Hematology Overview

Hematology is a specialized branch of medicine that focuses on the study, diagnosis, treatment, and prevention of blood-related disorders and diseases. It encompasses a wide range of conditions, including anemia, clotting disorders, leukemia, lymphoma, and myeloma. Hematologists work to understand the intricate components of blood, such as red blood cells, white blood cells, platelets, hemoglobin, and plasma, as well as the organs responsible for blood production, like the bone marrow, lymph nodes, and spleen. The field is integral to understanding the body’s immune system, oxygen transport, and coagulation processes, as these functions are closely tied to overall health. Advances in hematology, such as molecular diagnostics, targeted therapies, and bone marrow transplantation, have revolutionized the way hematologic diseases are managed.  

In recent years, hematology has witnessed significant breakthroughs, particularly in understanding the genetic and molecular basis of blood disorders. Cutting-edge therapies, including immunotherapy and gene editing technologies like CRISPR, are providing hope for patients with previously untreatable conditions. For instance, the development of antibody-drug conjugates and CAR-T cell therapies has improved outcomes for individuals with certain blood cancers. In addition, research into hematopoietic stem cell transplantation continues to expand, offering curative potential for diseases such as sickle cell anemia and severe aplastic anemia. As the field evolves, it not only enhances our understanding of blood and its disorders but also contributes to broader medical advancements in oncology, immunology, and regenerative medicine.

Hematology Market Insights

North America is anticipated to hold the largest share of the global hematology market. This dominance can be attributed to factors such as the growing prevalence of chronic blood disorders, a rising incidence of these conditions among the aging population, and advancements in product offerings, which collectively support the expansion of the hematology market in the region.  

The increasing number of blood disease cases underscores the demand for hematology in treatment, driving market growth in North America. Additionally, a strong focus on product innovation and the proactive efforts of device manufacturers to penetrate local markets through strategic partnerships contribute further to regional market development. These collaborations are likely to stimulate product demand. Consequently, a combination of factors—such as a large patient base, favorable reimbursement policies, and the introduction of new products—is expected to propel the growth of the North American hematology market during the forecast period.

To know more about why North America is leading the market growth in the hematology market, get a snapshot of the Hematology Market Outlook 

Hematology Market Dynamics

The hematology market has undergone significant evolution in recent years, driven by advancements in biotechnology, growing demand for precision medicine, and the increasing prevalence of hematologic disorders such as leukemia, lymphoma, and multiple myeloma. Hematology encompasses both diagnostics and therapeutics, making it a critical domain within healthcare. The rise in patient awareness and improvements in early detection technologies are boosting the diagnostic segment, while innovative treatments, including monoclonal antibodies, CAR-T therapies, and bispecific antibodies, dominate the therapeutic landscape. Additionally, the integration of genetic profiling into routine care has enabled tailored therapies, further propelling the market.

One of the key dynamics shaping the hematology market is the shift towards targeted therapies, particularly for rare blood disorders and cancers. Traditional chemotherapies are being replaced or supplemented by highly specific treatments that minimize side effects and improve efficacy. In diseases like hemophilia, the adoption of gene therapies and recombinant products has been transformative. Similarly, the field of immuno-oncology is gaining traction, with treatments like immune checkpoint inhibitors and antibody-drug conjugates showing promise in hematologic malignancies.

On the diagnostic side, the emergence of high-throughput technologies such as next-generation sequencing (NGS) and liquid biopsy has revolutionized disease detection and monitoring. These technologies allow for earlier diagnosis, better prognosis determination, and the ability to track disease progression or recurrence with higher accuracy. The growing demand for point-of-care (POC) diagnostics, especially in resource-limited settings, is further expanding the reach of hematology diagnostics to underserved populations.

Despite these advances, the market faces several challenges, including high costs associated with novel therapies and diagnostics, regulatory hurdles, and access disparities, particularly in low- and middle-income countries. The complexity of personalized treatments also necessitates robust healthcare infrastructure, which is not uniformly available across regions. Furthermore, the market is highly competitive, with pharmaceutical and biotech companies vying for leadership in niche indications, leading to intense research and development (R&D) activities.

Looking forward, the hematology market is expected to continue its growth trajectory, fueled by the integration of artificial intelligence (AI) and machine learning into research, diagnosis, and treatment development. These technologies have the potential to optimize patient outcomes and streamline healthcare delivery. Collaborations between academia, biotech firms, and pharmaceutical giants are likely to accelerate innovation, while regulatory frameworks are anticipated to evolve to better accommodate cutting-edge therapies. As the field advances, the hematology market remains a cornerstone of modern medicine, addressing unmet needs and improving quality of life for patients globally.

Get a sneak peek at the hematology market dynamics @ Hematology Market Dynamics Analysis

Hematology Market Assessment

• Hematology Market Segmentation
• Hematology Market Segmentation By Type: Instruments (Hematology Analyzers, Hematology Cell Counters, Flow Cytometers, Coagulation Analyzers, Others), Kits and Reagents
• Hematology Market Segmentation By Application: Cardiovascular Diseases, Auto-Immune Diseases, Cancer, Diabetes Mellitus, Infectious Diseases, Others
• Hematology Market Segmentation By Modality: Clinical Laboratory Devices, Point of Care Devices
• Hematology Market Segmentation By End User: Hospitals & Clinics, Diagnostic Laboratories, Others
• Hematology Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the hematology market are set to emerge as the trendsetter explore @ Hematology Companies 

Table of Contents 

Interested in knowing the hematology market by 2030? Click to get a snapshot of the Hematology Market Trends

Related Reports

Hematological Cancer Therapeutics Market

Hematological Cancer Therapeutics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key hematological cancer therapeutics companies, including Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Takeda Pharmaceutical Co. Ltd, Johnson & Johnson, Incyte Corporation, AstraZeneca PLC, Celldex Therapeutics Inc., Kite Pharma (Gilead Sciences), Atara Biotherapeutics, Celgene Corporation, Astellas, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, among others.

Coagulation Analyzers Market

Coagulation Analyzers Market Insights, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key coagulation analyzers companies, including Abbott Laboratories Inc., Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Nihon Kohden Corporation, Maccura Biotechnology Co., Ltd., Bio-Group Medical System, Genrui Biotech Inc., A&T Corporation, Stago Group, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BPC BioSed S.R.L., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International, Erba Group, ACON Laboratories, Inc., Haemonetics Corporation, among others.

Flow Cytometry Market

Flow Cytometry Market Insights, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key flow cytometry companies, including Thermo Fisher Scientific Inc., BD, Stratedigm, Inc, Bio-Rad Laboratories, Inc., Luminex Corporation., Miltenyi Biotec, Sysmex Corporation, Agilent Technologies, Inc., Sony Biotechnology Inc., bioMérieux SA, Enzo Life Sciences, Inc., Union Biometrica, Inc., Cytek Biosciences, Sartorius AG, Beckman Coulter, Inc., Apogee Flow Systems Ltd., Molecular Instruments, Inc., Integrated DNA Technologies, Inc., New England Biolabs (NEB), ACROBiosystems, among others.

Coagulation Factor Deficiency Market

Coagulation Factor Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key coagulation factor deficiency companies, including Novo Nordisk, Spark Therapeutics, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Biotest AG, Centessa Pharmaceuticals (Apcintex), Staidson Biopharma Inc., Ultragenyx Pharmaceutical, Bayer, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

Contact Us

Shruti Thakur

[email protected]

+14699457679

https://www.delveinsight.com/medical-devices

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/global-hematology-market-to-exhibit-growth-at-a-cagr-of-8-by-2030–delveinsight-302329744.html

Featured Image: Megapixl @ Lucadp

Disclaimer